3ICH.E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting [EB/OL].1994-10-27[2009-03-01] http://www.ich.org/LOB/media/MEDIA436.pdf. October 27 1994.
4ICH.E2D:Post-Approval Safety Data Management:Definitions and Standards for Expedited Reporting[EB/OL]. 2003-11-12 [2009-03-01]. http://www.ich.org/LOB/media/MEDIA631.pdf.
5CIOMS. CIOMS FORM [EB/OL].2009-07-03 [2009-03-01]. http://www.cioms.ch/cioms.pdf. 3 June 2009.
6WHO-UMC. The use of the WHO-UMC system for standardised case causality assessment. [EB/OL].2009-07-03[2009-03-01].http://www.who-umc.org/graphics/4409.pdf.
7ICH.E2B:Data Elements For Transmission Of Individual Case Safety Reports[EB/OL].2001-02-05[2009-03-01].http://www. ich.org/LOB/media/MEDIA2217.pdf.
8叶任高 沈清瑞.肾脏病诊断与治疗学[M].北京：人民卫生出版社,1996.125.
9Reitberg DP, Marble DA,Schuhz,RW, et al. Pharmacokinet- ics of Cefoperazone (2.0 g) and Sulbactam ( 1.0 g) Coad- ministered to Subjects with Normal Renal Function, Patients with Decreased Renal Function, and Patients with End-Stage Renal Disease on Hemodialysis [ J ]. Antimicrobial Agents and Chemotherapy, 1988,32(4) :503-509.
10Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestsations, potential pathogenic mechanisms,and the role of electroencephalographic monitoring[J]. Ann Phar- macother, 2008, 42(12) : 1843-1850.
